- β’ NICE NG28 (type 2 diabetes, updated 18 Feb 2026): for adults with type 2 diabetes and CKD with eGFR above 30, offer modified-release metformin plus an SGLT2 inhibitor. With eGFR 20β30, offer dapagliflozin or empagliflozin plus a DPP-4 inhibitor; below 20, consider a DPP-4 inhibitor. Metformin remains contraindicated below eGFR 30. Upshot: diabetic kidney patients should now almost all be on an SGLT2 inhibitor unless there's a reason not to.
- β’ NICE NG12 (suspected cancer, updated 15 Apr 2026): new non-site-specific rule β aged 60+ with unexplained weight loss of more than 5% over 6 months: assess, then offer urgent investigation, a suspected cancer pathway referral, or a non-specific symptoms pathway referral. The urological referral thresholds (PSA, haematuria, testis) are unchanged.
- β’ Also worth knowing (UK National Screening Committee, 28 May 2026 β not NICE): no population PSA screening. Targeted screening is recommended only for men aged 45β61 with a BRCA2 variant and a relevant family history (PSA every 2 years) β it isn't running yet; governments must first accept it.
Sources: NICE NG28 (Feb 2026); NICE NG12 update information (Apr 2026); UK NSC final recommendation reported by Cancer Research UK (28 May 2026).
Renal & Urology for GPs: Your Essential Guide
Every surgery has at least one "wee" problem a day β this page helps you spot the ones that are bigger than they look.
Last Updated: 19 September 2026
Executive Summary: What You'll Master Today
Because you have 47 other things to do before lunch, and that's just the morning list
What This Page Covers:
- β’History & examination
- β’Investigations & the PSA test
- β’Differential frameworks
- β’Urinary tract infections
- β’Haematuria & proteinuria
- β’Acute kidney injury
- β’Chronic kidney disease
- β’Urinary tract stones
- β’Male LUTS & BPH
- β’Overactive bladder & incontinence
- β’Urological cancers
- β’Red flags & emergencies
Quick Facts at a Glance:
Sources: NHS PSA test page; Health Survey for England 2016 (34% of over-75s CKD G3β5, cited in NICE NG203 scope); NICE NG148 context; Wilcox et al, BJGP 2020.
π₯ Downloads & Resources
Useful downloads and trusted web links for renal & urology
π₯ Downloads
path: URORENAL
- BPH & LUTS Management Pathway.pdf
- chronic kidney disease management - affinity care 2022.pptx
- CKD - Progression & Complications.pptx
- CKD Annual Review - checklist.docx
- CKD Criteria & Targets - quick reference guide.docx
- CKD Diagnosis Staging and Comprehensive Assessment.pptx
- CKD Discussions with Patients - explanations.docx
- CKD Management in Primary Care.pptx
- Continence Top Tips.docx
- Foods Which Irritate the Bladder.pdf
- Haematuria & Proteinuria.pptx
- medications to be careful with in CKD - affinity care 2022.pptx
- Prescribing in CKD & SADMAN.pptx
- Prostate Examination - what should it feel like.pdf
- Prostate Symptom Score - IPSS.pdf
- Prostate, BPH and PSA - everthing you wanted to know.pptx
- PSA Counselling Guide.pdf
- PSA Counselling.docx
- PSA Values.pdf
- UTI Antibiotic Prophylaxis.docx
This shortcode is replaced automatically by WordPress.
π Web Resources
- NICE CKS β Kidney Disease & Urology
Primary-care summaries for every topic on this page.
- NICE NG12 β Suspected Cancer
Suspected cancer pathway thresholds (renal, bladder, prostate, testis).
- NICE NG203 β Chronic Kidney Disease
Classification, monitoring, BP targets and referral.
- NICE NG28 β Type 2 Diabetes (2026)
New metformin + SGLT2 inhibitor pathway, including CKD.
- NICE NG148 β Acute Kidney Injury
Prevention, detection and management.
- NICE NG109 β Lower UTI Prescribing
See also NG110 (prostatitis), NG111 (pyelonephritis), NG112 (recurrent), NG113 (catheter).
- NICE NG118 β Renal & Ureteric Stones
Analgesia, imaging, expulsive therapy and prevention.
- NICE CG97 β LUTS in Men
Assessment and stepwise drug treatment.
- NICE NG123 β Incontinence in Women
Pelvic floor training, bladder training, OAB drugs.
- BNF
Check every dose, renal adjustment and interaction here.
- Think Kidneys β AKI
NHS AKI programme resources and patient materials.
- Prostate Cancer UK β PSA for Professionals
Balanced PSA information to share with men.
π Quick Navigation
π§ Brainy Bites: Essential Renal & Urology Wisdom
The stuff seasoned GPs wish someone had told them sooner
1οΈβ£ History & Examination Tips
Must-ask questions and exam structure for the commonest urinary presentations
Focused histories and the examination
Open one at a time β each gives you the questions, the traps, and what to say.
Essential questions
- β’Onset & timing: sudden vs gradual; linked to intercourse?
- β’Associated: frequency, urgency, new nocturia, cloudy urine, visible blood
- β’Vaginal or urethral discharge/itch: points away from UTI
- β’Sexual history: new partner, STI risk
- β’Systemic: fever, rigors, loin pain, vomiting (think pyelonephritis)
- β’Pregnancy, catheter, recent antibiotics and past cultures
Differential lens
- β’Infective: bacterial UTI, STI (chlamydia, gonorrhoea), prostatitis
- β’Non-infective: bladder pain syndrome, chemical irritants
- β’Structural: stone, tumour, urethral stricture
- β’Hormonal: genitourinary syndrome of menopause (vaginal atrophy)
LUTS (lower urinary tract symptoms) is the umbrella term for bladder and outflow symptoms. Sort them into three buckets so you don't miss anything.
Storage
- β’Frequency
- β’Nocturia
- β’Urgency Β± urge leakage
Voiding
- β’Hesitancy
- β’Poor or intermittent stream
- β’Straining
Post-micturition
- β’Incomplete emptying
- β’Post-void dribble
Scrotal pain or swelling
- β’Onset: sudden (torsion) vs gradual (epididymo-orchitis)
- β’Nausea/vomiting: leans towards torsion
- β’Fever, dysuria, discharge: leans towards infection
Lumps β structured examination
- β’Can you get above it? If not, think inguinal hernia
- β’Separate from the testis? epididymal cyst β usually benign
- β’Transilluminates? fluid (hydrocele/cyst) vs solid
- β’Within the testis and hard? treat as cancer until proven otherwise
- β’Pattern: gradual loss suggests vascular cause; sudden onset with preserved morning erections suggests psychological
- β’Risk factors: diabetes, hypertension, smoking, lipids β ED can come before heart disease
- β’Drugs: beta-blockers, thiazides, SSRIs, 5Ξ±-reductase inhibitors
- β’Check: HbA1c, lipids, cardiovascular risk, morning testosterone where indicated (NICE CKS)
- β’Abdomen: palpable (and dull-to-percussion) bladder = retention; ballotable kidney = mass or hydronephrosis
- β’Obs: temperature, pulse and BP β sepsis and hypertension both matter here
- β’Genitals: phimosis, meatal stenosis, testicular lumps; in women, vaginal atrophy and prolapse
DRE (digital rectal examination) β you're judging size, surface, symmetry and consistency. Always offer a chaperone and document it.
What benign feels like
- β’Smooth, symmetrical, rubbery (like the tip of your nose)
- β’Central groove still present
- β’BPH: smoothly and evenly enlarged
What worries you
- β’Hard, craggy or nodular
- β’Asymmetry, lost central groove
- β’Tender and boggy with fever = acute prostatitis (examine gently)
π© Red Flags β Do Not Miss
Prostate feels malignant on DRE β suspected cancer pathway referral, whatever the PSA (NICE NG12).
Painless distended bladder β chronic retention; check U&E for obstructive kidney injury.
2οΈβ£ Investigations & the PSA Test
Urine testing, kidney bloods, and the PSA conversation done properly
First-line tests in the room
Cheap, fast and often decisive β but each has traps.
Reading it well
- β’Nitrite + leucocytes: support UTI (nitrite comes from Gram-negative bacteria)
- β’Blood: exclude menstruation and contamination; 1+ or more needs follow-up (NICE NG203)
- β’Protein: confirm and quantify with a urine ACR β not the strip
- β’Glucose: an opportunistic diabetes clue
Pitfalls
- β’Negative nitrite doesn't exclude UTI β some organisms don't make it
- β’Don't dip over-65s or catheterised patients to diagnose UTI β bacteria in the bladder are common and harmless there (UKHSA)
- β’Treat the patient, not the strip β asymptomatic bacteriuria isn't treated, except in pregnancy
Sources: UKHSA "UTI: diagnostic tools for primary care"; NICE NG203 (haematuria testing).
- β’U&E + eGFR: baseline before and 1β2 weeks after starting an ACEi/ARB, and for any AKI/CKD question
- β’Urine ACR: the test for proteinuria β early-morning sample preferred (NICE NG203)
- β’FBC: anaemia (CKD, cancer), raised white count (infection)
- β’HbA1c & lipids: cardiovascular and renal risk
- β’Calcium: in anyone with kidney stones (NICE NG118)
NICE age-specific PSA thresholds for referral (NG12)
For men with possible symptoms, refer on a suspected cancer pathway (the old "2-week wait") if PSA is above the age-specific range, or the prostate feels malignant.
| Age (years) | Refer if PSA above (Β΅g/L) |
|---|---|
| Under 40 | Use clinical judgement |
| 40β49 | 2.5 |
| 50β59 | 3.5 |
| 60β69 | 4.5 |
| 70β79 | 6.5 |
| 80 and over | Use clinical judgement β most men this age have a focus of cancer; diagnose only if it's likely to need treatment |
Things that falsely raise PSA
- β’Ejaculation or vigorous exercise in the last 48 hours
- β’Urine infection β wait at least 1 month after treatment
- β’DRE in the last week; prostate biopsy in the last 6 weeks
- β’BPH, prostatitis, catheterisation, increasing age
Things that falsely lower it
- β’5Ξ±-reductase inhibitors (finasteride, dutasteride) roughly halve PSA after about 6 months
Sources: NICE NG12 (thresholds defined 2021; guideline last updated Apr 2026); GPnotebook summary of NG12; NHS PSA test pre-test advice.
Cover the trade-offs
- β’False alarms lead to MRI Β± biopsy and worry
- β’False reassurance: a normal PSA doesn't rule cancer out
- β’Overdiagnosis: many cancers found would never have caused harm
- β’Treatment harms: incontinence and erection problems
Who to test (with counselling)
- β’Symptoms: any LUTS, erectile dysfunction or visible haematuria β PSA + DRE (NICE NG12)
- β’No symptoms but asking: informed choice after balanced information
- β’Higher risk: Black men, family history, BRCA2 β discuss earlier
Sources: NHS PSA test page (3 in 4; 1 in 7); NICE NG12; UK NSC final recommendation, 28 May 2026 (via Cancer Research UK).
π Aide-mΓ©moire β tap a card to flip
3οΈβ£ Differential Diagnosis Frameworks
Mental scaffolds so nothing important falls through the gaps
Three frameworks worth memorising
Each one maps straight onto a management decision.
Painful
- β’UTI: dysuria, frequency, urgency
- β’Stone: loin-to-groin colic, can't keep still
- β’Prostatitis: perineal pain, fever
- β’Trauma or instrumentation
Painless (think cancer first)
- β’Bladder cancer: older, smoker
- β’Kidney cancer: mass, weight loss
- β’Prostate: BPH or cancer
- β’Glomerular disease: with protein, high BP
Pre-renal (commonest)
- β’Dehydration: D&V, bleeding, sepsis
- β’Heart failure, cirrhosis
- β’Drugs: ACEi/ARB, NSAIDs, diuretics
Renal (intrinsic)
- β’Acute tubular necrosis
- β’Glomerulonephritis / vasculitis
- β’Drug-induced interstitial nephritis (e.g. PPIs)
Post-renal (blockage)
- β’Prostate enlargement or cancer
- β’Stones, strictures, pelvic mass
- β’Blocked catheter, clot retention
| Condition | Key clues | Action |
|---|---|---|
| Torsion | Sudden severe pain, vomiting, high-riding testis | Immediate surgical referral |
| Epididymo-orchitis | Gradual pain, fever, dysuria/discharge | Antibiotics per STI/UTI likelihood (CKS) |
| Hydrocele | Transilluminates, can get above it | Ultrasound if testis not palpable |
| Epididymal cyst | Separate lump above/behind testis | Reassure; ultrasound if unsure |
| Varicocele | "Bag of worms", usually left, goes on lying | Reassure; image if new or doesn't drain |
| Testicular cancer | Hard, painless lump in the testis | Suspected cancer pathway + urgent ultrasound |
4οΈβ£ Urinary Tract Infections (UTI)
Right drug, right duration, right patient β with good antibiotic stewardship
UTI by patient group
All doses are adult oral doses from NICE's antimicrobial prescribing guidelines. Check the BNF for renal/hepatic impairment and your local resistance data.
- 1stNitrofurantoin 100 mg modified-release twice a day for 3 days (or 50 mg four times a day if MR unavailable) β only if eGFR β₯45.
- 1stTrimethoprim 200 mg twice a day for 3 days β only if low risk of resistance (e.g. not used in the past 3 months).
- 2ndPivmecillinam 400 mg initial dose, then 200 mg three times a day (3 days in total) or fosfomycin 3 g single-dose sachet β if no improvement after 48 hours or first choice unsuitable.
Send an MSU ifβ¦
- β’Pregnant, male, recurrent UTI, or treatment failure
- β’Atypical symptoms or visible haematuria
- β’Suspected pyelonephritis or recent resistant organisms
Self-care & back-up options
- β’Paracetamol or ibuprofen for pain; drink enough to avoid dehydration
- β’NG109 allows a back-up (delayed) prescription for non-pregnant women with milder symptoms
Source: NICE NG109 (lower UTI: antimicrobial prescribing), tables 1β2.
- 1stTrimethoprim 200 mg twice a day for 7 days, or nitrofurantoin 100 mg MR twice a day for 7 days (eGFR β₯45).
- 2ndNo improvement after 48 hours: consider an alternative diagnosis (prostatitis, pyelonephritis, STI) and use culture results.
- 1stCiprofloxacin 500 mg twice a day for 14 days then review (or ofloxacin 200 mg twice a day).
- AltIf a fluoroquinolone is unsuitable: trimethoprim 200 mg twice a day for 14 days then review.
- 2ndAfter specialist advice: levofloxacin 500 mg once a day or co-trimoxazole 960 mg twice a day, each for 14 days then review.
Sources: NICE NG109 table 3; NICE NG110; MHRA Drug Safety Update, Jan 2024.
Pyelonephritis (kidney infection) = fever, loin pain, rigors, nausea/vomiting Β± lower urinary symptoms. Send an MSU and consider admission.
- 1stCefalexin 500 mg twice or three times a day (up to 1β1.5 g three or four times a day if severe) for 7β10 days.
- AltCo-amoxiclav 500/125 mg three times a day for 7β10 days β only if culture shows susceptibility.
- AltTrimethoprim 200 mg twice a day for 14 days β only if culture shows susceptibility.
- AltCiprofloxacin 500 mg twice a day for 7 days β only if the others are unsuitable (MHRA warning above).
π© Red Flags β Do Not Miss
Signs of sepsis (confusion, low BP, high heart or breathing rate), vomiting, or pregnancy β refer to hospital the same day.
Fever + loin pain with a known or suspected stone β possible infected obstructed kidney: emergency urology.
Source: NICE NG111 (acute pyelonephritis: antimicrobial prescribing).
- 1stNitrofurantoin 100 mg MR twice a day for 7 days (eGFR β₯45) β avoid at term (risk of neonatal haemolysis).
- 2ndAmoxicillin 500 mg three times a day for 7 days (only if culture shows susceptibility) or cefalexin 500 mg twice a day for 7 days.
Sources: NICE NG109 table 2; BNF (trimethoprim, pregnancy).
Recurrent UTI = 2 or more in 6 months, or 3 or more in 12 months. Look for a cause first β refer men, and anyone with visible haematuria or suspected structural problems.
π NICE NG112 β the stepwise ladder (non-pregnant women)
- SingleAfter a trigger: trimethoprim 200 mg or nitrofurantoin 100 mg (eGFR β₯45) as one dose.
- Non-abxMethenamine hippurate 1 g twice a day; review within 6 months, then every 12 months. Seek specialist advice first in pregnancy, men, or recurrent upper/complicated UTI.
- Daily 1stTrimethoprim 100 mg at night or nitrofurantoin 50β100 mg at night (eGFR β₯45).
- Daily 2ndAmoxicillin 250 mg at night or cefalexin 125 mg at night.
Sources: NICE NG112 (recurrent UTI, amended 2024, visual summary); methenamine dosing as used in the ALTAR trial reviewed by NICE; BNF.
Prevention
- β’Catheterise only when needed; remove as soon as possible
- β’Aseptic insertion; keep a closed drainage system
- β’No routine antibiotic prophylaxis
Diagnosis & first steps
- β’Treat only if symptomatic β never on a dipstick
- β’Catheter in over 7 days? Change it promptly (don't delay antibiotics) and take the sample from the new one
- No upper1st: nitrofurantoin 100 mg MR twice a day (eGFR β₯45) or trimethoprim 200 mg twice a day (low resistance risk), each for 7 days. 2nd: pivmecillinam 400 mg then 200 mg three times a day (7 days in total).
- UpperFever/loin pain: cefalexin 500 mg twice or three times a day for 7β10 days; alternatives as for pyelonephritis.
Source: NICE NG113 (catheter-associated UTI: antimicrobial prescribing).
π Aide-mΓ©moire β how many days?
5οΈβ£ Haematuria & Proteinuria
Who needs urology, who needs nephrology, and who needs neither
Blood and protein in the urine
Haematuria is a symptom, not a diagnosis.
Visible haematuria = blood the patient can see. Higher cancer risk than non-visible.
First confirm it's really blood from the urinary tract
- β’Exclude periods and vaginal bleeding; beetroot and rifampicin colour urine red
- β’Send an MSU; check FBC and U&E/eGFR
- β’Clots or heavy bleeding? Risk of clot retention
Pain helps localise
- β’Painful: UTI, stone, clot colic
- β’Painless: cancer until proven otherwise
π© Suspected cancer pathway referral (NICE NG12)
Aged 45+ with unexplained visible haematuria without UTI, or visible haematuria that persists or recurs after successful UTI treatment β bladder and kidney cancer pathway.
Non-visible haematuria = blood on the dipstick only. Use a dipstick rather than microscopy, and act on 1+ or more (NICE NG203).
Confirm & classify
- β’Persistent = 2 out of 3 positive dipsticks (NICE NG203)
- β’Exclude UTI, periods and recent heavy exercise
- β’Every time: BP, eGFR and urine ACR
Don't be misled
- β’Anticoagulants don't explain it β investigate anyway
- β’Young adult with cola-coloured urine after a sore throat β think glomerulonephritis (nephrology, not urology)
π© Suspected cancer pathway referral (NICE NG12)
Aged 60+ with unexplained non-visible haematuria and either dysuria or a raised white cell count on a blood test β bladder cancer pathway.
Consider a non-urgent bladder cancer referral at 60+ with recurrent or persistent unexplained UTI.
| ACR (mg/mmol) | Category | What to do |
|---|---|---|
| Under 3 | A1 β normal to mildly increased | Usual risk-factor care |
| 3β30 | A2 β moderately increased | Confirm on early-morning sample; this is clinically important |
| Over 30 | A3 β severely increased | Treat, monitor more often; ACEi/ARB if hypertensive |
| 70 or more | (within A3) | Refer nephrology (unless explained by treated diabetes) |
- β’Confirm: if the first ACR is 3β70, repeat on an early-morning sample; if 70 or more, no repeat needed.
- β’Clinically important proteinuria = confirmed ACR of 3 or more.
Source: NICE NG203 (CKD: assessment and management).
π Haematuria β urology, nephrology or monitor?
(visible at 45+; or non-visible at 60+ with dysuria / raised WCC)
Sources: NICE NG12 (cancer referral) and NG203 (nephrology referral).
π Aide-mΓ©moire β tap to reveal the threshold
6οΈβ£ Acute Kidney Injury (AKI)
Spot it early, stop the culprits, and know who needs hospital today
AKI in primary care
Usually silent, often drug-related, frequently preventable.
Definition β any one of (NICE NG148)
- β’Creatinine rise of 26 Β΅mol/L or more within 48 hours
- β’Creatinine rise of 50% or more within the past 7 days
- β’Urine output under 0.5 mL/kg/hour for over 6 hours
Who's at risk?
- β’Age 65+, CKD, heart failure, liver disease, diabetes
- β’Previous AKI; cognitive impairment (can't keep drinking)
- β’Nephrotoxic drugs; sepsis; urinary obstruction
| Stage | Creatinine | Urine output | Primary-care action |
|---|---|---|---|
| 1 | 1.5β1.9Γ baseline, or rise of 26 Β΅mol/L or more | Under 0.5 mL/kg/h for 6β12 h | Find and treat cause; stop culprits; recheck in 24β48 h |
| 2 | 2.0β2.9Γ baseline | Under 0.5 mL/kg/h for 12 h or more | Low threshold to admit; discuss with medicine |
| 3 | 3Γ baseline, or 354 Β΅mol/L or more | Under 0.3 mL/kg/h for 24 h, or anuria for 12 h | Hospital admission |
Staging per KDIGO criteria, as used by the NHS England AKI algorithm and NICE NG148.
What you do
- β’Assess hydration, sepsis and obstruction (feel for a bladder)
- β’Dipstick the urine β blood/protein hints at kidney inflammation
- β’Pause nephrotoxic and "sick-day" drugs
- β’Recheck U&E promptly; review all drug doses by eGFR
After recovery
- β’Recheck eGFR and ACR β AKI raises future CKD risk
- β’Restart held medicines deliberately, with a blood-test plan
- β’Code the AKI so the next clinician knows
π© Red Flags β same-day admission / specialist discussion
Hyperkalaemia (potassium 6.0 mmol/L or more), fluid overload, or uraemic symptoms.
Signs of kidney inflammation: blood and protein on dipstick with rapidly falling eGFR, new swelling or high BP β possible glomerulonephritis.
Suspected obstruction (anuria, palpable bladder, known pelvic cancer), or AKI stage 3, or sepsis.
Source: NICE NG148 (AKI: prevention, detection and management).
ACE inhibitors and ARBs relax the outflow vessel of the kidney's filter β that's how they protect it long-term β so a small eGFR dip on starting is expected. Recheck U&E 1β2 weeks after starting or increasing the dose.
Source: NICE NG203, recommendations on reninβangiotensin system antagonists.
π§ Mnemonic: SADMANS β medicines to pause on "sick days"
Sources: Think Kidneys / NHS England AKI programme; NICE NG148; NICE NG28 (2026). The mnemonic is a teaching aid, not NICE wording.
7οΈβ£ Chronic Kidney Disease (CKD)
A cardiovascular disease that happens to involve the kidneys
CKD from diagnosis to referral
Most people with CKD are managed entirely in general practice β this is your territory.
What untreated CKD leads to
- β’Hard-to-control blood pressure β heart attack, stroke, heart failure, peripheral arterial disease
- β’Hypoglycaemia risk β the kidneys normally clear insulin and some diabetes drugs
- β’Fluid retention, anaemia, and bone and mineral problems in later stages
- β’Drug accumulation β many doses need adjusting as eGFR falls
Classify using both eGFR (G) and ACR (A) β for example, eGFR 50 and ACR 35 = G3aA3. Risk rises with both.
| GFR category | eGFR (mL/min/1.73mΒ²) | Meaning |
|---|---|---|
| G1 | 90 or more | Normal or high (CKD only if damage markers present) |
| G2 | 60β89 | Mildly reduced (CKD only if damage markers present) |
| G3a | 45β59 | Mildly to moderately reduced |
| G3b | 30β44 | Moderately to severely reduced |
| G4 | 15β29 | Severely reduced |
| G5 | Under 15 | Kidney failure |
How often to check eGFR (tests per year, NICE NG203)
| GFR category | ACR A1 (under 3) | ACR A2 (3β30) | ACR A3 (over 30) |
|---|---|---|---|
| G1βG2 | 1 or fewer | 1 | 1 or more |
| G3a | 1 | 1 | 2 |
| G3b | 1β2 | 2 | 2 or more |
| G4 | 2 | 2 | 3 |
| G5 | 4 | 4 | 4 or more |
Source: NICE NG203 (classification; monitoring frequency table). Replaces the old fixed "3-monthly / monthly" schedules in the previous page.
Offer testing β eGFR (from creatinine) plus urine ACR β to people with risk factors. Just two tests do the job.
Test people with (NICE NG203)
- β’Diabetes, hypertension, cardiovascular disease
- β’Previous AKI
- β’Structural renal tract disease, recurrent stones, prostate enlargement
- β’Multisystem disease (e.g. lupus), gout
- β’Family history of kidney failure or hereditary kidney disease
- β’Incidental haematuria or proteinuria
- β’Long-term nephrotoxic drugs (e.g. lithium, calcineurin inhibitors, long-term NSAIDs)
Don't test just because of
- β’Age, sex, ethnicity or obesity alone, without another risk factor
Lifestyle β what to say
- β’Exercise, healthy weight, stop smoking β the same advice that protects the heart protects the kidneys
- β’Salt: keep to under 6 g a day, as for high blood pressure
- β’Protein: don't offer low-protein diets β NICE advises against restricting protein below 0.6β0.8 g/kg/day
- β’Painkillers: avoid regular over-the-counter NSAIDs; check with a pharmacist before buying remedies
- β’Diabetes: individualised HbA1c targets β usually 48 or 53 mmol/mol, relaxed in frailty (NICE NG28)
Sources: NICE NG203 recs 1.6.1β1.6.2 (BP) and lifestyle recommendations; NICE NG28; NICE NG136. Replaces older non-UK dietary and glucose targets from the previous page.
- β’Diabetes and ACR over 3
- β’Hypertension and ACR over 30
- β’ACR 70 or more, whatever the BP (and refer)
- 1stRamipril β start 1.25β2.5 mg once daily, titrate to the highest licensed dose tolerated (max 10 mg once daily). In renal impairment the BNF caps it at 5 mg daily if eGFR 30β60 and starts at 1.25 mg if eGFR under 30.
- 2ndIf an ACEi isn't tolerated (e.g. cough): losartan 50 mg once daily, increased to 100 mg once daily if needed (start 25 mg if volume-depleted).
- β’Dapagliflozin 10 mg once daily (NICE TA1075, 2025) as an add-on to an optimised ACEi/ARB if eGFR 20 to under 45, or eGFR 45β90 with ACR 22.6 or more or type 2 diabetes β diabetic or not.
- β’Empagliflozin 10 mg once daily (NICE TA942) is the alternative; use the least expensive suitable option.
- β’Full eligibility, starting checklist and safety advice: see the Gliflozins (SGLT2i) tab.
Sources: NICE NG203; NICE TA1075 (Jul 2025); NICE TA942; NICE TA877; NICE NG238; BNF / SPC (ramipril, losartan).
Gliflozins (SGLT2 inhibitors) in kidney disease β the 2026 picture
Gliflozins were designed to lower glucose by making the kidneys pass sugar in the urine. The surprise was that they also slow kidney decline and protect the heart β even in people without diabetes. That's why NICE now uses them for CKD, heart failure and type 2 diabetes.
Who qualifies? Three NICE routes
| Route | Who | Key conditions |
|---|---|---|
| CKD β TA1075 (dapagliflozin, 2025) & TA942 (empagliflozin, 2023) | Adults with CKD, with or without diabetes | Add-on to highest tolerated ACEi/ARB (unless contraindicated) and eGFR 20 to under 45, or eGFR 45β90 with ACR 22.6+ or type 2 diabetes. Use the least expensive suitable option. |
| Type 2 diabetes + CKD β NG28 (Feb 2026) | Adults with type 2 diabetes and CKD | eGFR over 30: modified-release metformin + SGLT2i. eGFR 20β30: dapagliflozin or empagliflozin + DPP-4 inhibitor. Continue for heart/kidney benefit even if not helping glucose. |
| Heart failure β TA679/TA773 (HFrEF) & TA902/TA929 (HFmrEF/HFpEF) | Symptomatic chronic heart failure, any ejection fraction | HFrEF (EF 40% or less): add-on to optimised standard care. HFmrEF/HFpEF (EF over 40%): in addition to standard care. Many CKD patients also qualify here. |
Sources: NICE TA1075 (Jul 2025), TA942 (Dec 2023), NG28 (Feb 2026), TA679, TA773, TA902, TA929.
Which drug, what dose?
- 1stDapagliflozin 10 mg once daily, long term. No dose change for kidney function. Don't start if eGFR is under 15 (experience starting under 25 is limited). Starting dose 5 mg only in severe liver impairment.
- 2ndEmpagliflozin 10 mg once daily, long term. Don't start if eGFR is under 20. If eGFR is under 60 the dose stays at 10 mg (the 25 mg dose is for glucose control with eGFR 60+ only).
- BothNo routine lower "stop" threshold is set in the SPCs β as eGFR nears 15 or dialysis approaches, take renal advice rather than stopping reflexively.
π Starting a gliflozin in primary care β checklist
π© Safety β MHRA advice every prescriber should know
Diabetic ketoacidosis can happen with near-normal glucose ("euglycaemic DKA"). If someone on an SGLT2i has nausea, vomiting, abdominal pain, breathlessness or feels very unwell β test ketones, even if glucose looks fine (MHRA 2016).
Stop during major surgery or acute serious illness in hospital and check ketones, preferably in blood. Restart once ketones are normal and the patient is stable (MHRA 2020).
Fournier's gangrene (necrotising infection of the genitals/perineum) β rare but life-threatening. Severe genital or perineal pain, redness or swelling with fever: stop the drug and refer urgently (MHRA 2019).
Foot care: a lower-limb amputation signal was seen with canagliflozin; not shown with dapagliflozin or empagliflozin but may be a class effect β keep up diabetic foot checks (MHRA 2017).
π Aide-mΓ©moire β gliflozins
Sources: NICE TA1075, TA942, NG28 (2026), TA679, TA773, TA902, TA929; Forxiga and Jardiance UK SPCs (emc); MHRA Drug Safety Updates 2016, 2017, 2019, 2020.
- eGFR >30Modified-release metformin + an SGLT2 inhibitor (introduce one at a time, metformin first). SGLT2 inhibitor alone if metformin unsuitable.
- eGFR 20β30Dapagliflozin or empagliflozin + a DPP-4 inhibitor.
- eGFR <20Consider a DPP-4 inhibitor; if unsuitable, pioglitazone or insulin.
- NextNeed more glucose-lowering? Consider adding a DPP-4 inhibitor; then pioglitazone, a sulfonylurea or insulin.
Sources: NICE NG28 (Feb 2026, CKD track); UK metformin SPC renal dosing table; BNF.
π© Refer to nephrology (NICE NG203)
5-year risk of needing dialysis over 5% on the 4-variable Kidney Failure Risk Equation (KFRE) β this replaced the old "eGFR under 30" trigger.
ACR 70 or more β unless known to be caused by diabetes and already appropriately treated.
ACR over 30 with haematuria.
Sustained eGFR fall of 25% or more with a category change within 12 months, or a fall of 15 or more per year.
Hypertension uncontrolled despite 4 or more drugs at therapeutic doses.
Known or suspected rare/genetic kidney disease, or suspected renal artery stenosis.
Plan 6β8 weeks ahead. Many people who could be exempt will still choose to fast β respect that and make it safer.
Source: British Islamic Medical Association (BIMA) Ramadan guidance and published nephrology risk stratification. NICE does not cover fasting β this is specialist/consensus guidance.
π Aide-mΓ©moire β CKD numbers
8οΈβ£ Urinary Tract Stones
Pain relief first, spot the septic blocked kidney, then prevent the next one
Renal & ureteric colic
The patient who can't lie still, pacing your consulting room.
- 1stAn NSAID by any route (e.g. diclofenac) unless contraindicated. NG118 doesn't state a dose β use the BNF dose for the route you choose.
- 2ndIntravenous paracetamol if NSAIDs are contraindicated or not enough (hospital setting).
- 3rdOpioid only if both of the above are contraindicated or ineffective.
- Don'tDon't offer antispasmodics (e.g. hyoscine butylbromide) for stone pain.
Confirm & assess
- β’Low-dose non-contrast CT within 24 hours is the imaging of choice (ultrasound first in pregnancy and children)
- β’Dipstick blood is common, but its absence doesn't rule out a stone
- β’U&E, FBC/CRP, calcium; pregnancy test where relevant
- β’Older patient with "first renal colic"? Consider a leaking aortic aneurysm
Medical expulsive therapy (MET)
- β’Consider an alpha-blocker for distal ureteric stones under 10 mm (NICE NG118)
- β’Usually tamsulosin 400 micrograms once daily β off-label for this use; NG118 doesn't set a duration, so agree review with urology
- β’Small stones often pass on their own β watchful waiting is reasonable if pain is controlled
Source: NICE NG118 (renal and ureteric stones: assessment and management); BNF.
π© Red Flags β admit / urology today
Fever or sepsis with a suspected stone β an infected, blocked kidney needs emergency drainage (stent or nephrostomy).
AKI, anuria, a single or transplanted kidney, or stones on both sides.
Pain or vomiting uncontrolled despite adequate analgesia; pregnancy.
Everyone who's had a stone (NICE NG118)
- β’Drink 2.5β3 litres of water a day (more in heat)
- β’Add fresh lemon juice; avoid fizzy drinks
- β’Salt no more than 6 g a day
- β’Don't restrict calcium β keep a normal 700β1,200 mg a day
- β’Consider stone analysis; check serum calcium
Recurrent calcium oxalate stones
- β’1st: consider potassium citrate for recurrent stones that are mainly (over 50%) calcium oxalate
- β’2nd/targeted: consider a thiazide if there's also hypercalciuria β after salt is cut to 6 g a day
- β’NG118 doesn't give doses β usually specialist-led; check the BNF, and watch potassium/eGFR
Sources: NICE NG118 (prevention of recurrence); recurrence figure from Wilcox et al, BJGP 2020.
9οΈβ£ Male LUTS & Benign Prostatic Enlargement
Assess, reassure, and step up treatment logically
Lower urinary tract symptoms in men
BPH (benign prostatic hyperplasia) is common, but not every male LUTS is the prostate.
Assess (NICE CG97)
- β’History: storage vs voiding vs post-micturition; drugs; fluids
- β’IPSS score and how bothered he is
- β’Abdomen, genitals and DRE
- β’Frequencyβvolume chart if storage symptoms or nocturia
Test
- β’Urine dipstick (blood, glucose, infection)
- β’U&E if chronic retention, recurrent UTI, stones or kidney concern suspected
- β’PSA after counselling (LUTS is an NG12 indication)
- β’Fluids: sensible amounts, less in the evening; cut caffeine and alcohol
- β’Bladder training for storage symptoms; urethral milking for post-void dribble
- β’Review drugs β anticholinergics, diuretic timing; treat constipation
- β’Containment products (pads, sheaths) while other treatment starts
| Drug class | When (NICE CG97) | 1st choice | 2nd choice | Onset & watch-outs |
|---|---|---|---|---|
| Alpha-blocker | Moderateβsevere voiding LUTS | Tamsulosin 400 micrograms MR once daily | Alfuzosin 10 mg MR once daily | Daysβweeks; review at 4β6 weeks. Dizziness, postural drop, ejaculatory change; warn before cataract surgery (floppy iris) |
| 5Ξ±-reductase inhibitor | Prostate estimated over 30 g or PSA over 1.4 ng/mL, at high risk of progression | Finasteride 5 mg once daily | Dutasteride 500 micrograms once daily | 3β6 months to work. Halves PSA. Reduced libido, erectile dysfunction |
| Combination | Bothersome moderateβsevere LUTS + large prostate/PSA over 1.4 | Alpha-blocker + 5-ARI (e.g. tamsulosin + finasteride) | Best at preventing progression and retention | |
| Antimuscarinic | Storage (OAB) symptoms persist after alpha-blocker | See Overactive Bladder section for choices and doses | Check post-void residual concerns | |
Sources: NICE CG97 (last reviewed Dec 2024); BNF / regional formulary doses.
Refer β urgent or soon
- β’Acute retention; chronic retention with kidney impairment
- β’Recurrent UTI, bladder stones, visible haematuria
- β’Suspected cancer (see Urological Cancers)
- β’Suspected neurological cause
Consider referral
- β’Bothersome symptoms despite medical treatment
- β’He'd prefer a definitive (surgical) option
- β’Stress incontinence in men
π Overactive Bladder & Incontinence
Name the type, start conservative, and prescribe carefully in older people
Urinary incontinence
Common, under-reported, and very treatable β ask about it.
Stress incontinence
- β’Leaks on cough, sneeze, laugh, exercise, lifting β no warning urge
- β’Weak urethral sphincter and pelvic floor support
- β’Risk factors: childbirth, menopause, obesity, chronic cough
Urgency incontinence / overactive bladder (OAB)
- β’Sudden strong urge, then a leak; frequency and nocturia
- β’Caused by an overactive bladder muscle (detrusor)
- β’Triggers: key in the door, running water, cold
For OAB / urgency (NICE NG123)
- β’Bladder training for at least 6 weeks β gradually lengthen time between voids
- β’Cut caffeine; sensible fluids (not too much, not too little)
- β’Weight loss if BMI over 30; treat constipation
For stress incontinence (NICE NG123)
- β’Supervised pelvic floor muscle training for at least 3 months β at least 8 contractions, 3 times a day
- β’Refer to a specialist continence physiotherapist
- β’Weight loss if BMI over 30
Source: NICE NG123 (urinary incontinence and pelvic organ prolapse in women).
- 1stOxybutynin (immediate-release) 5 mg two or three times a day, maximum 5 mg four times a day; older people start at 2.5 mg twice a day. Not for frail older women (NICE NG123).
- 1st altTolterodine 2 mg twice a day (1 mg twice a day if side effects).
- 2ndSolifenacin 5 mg once daily, increased to 10 mg once daily if needed.
Sources: NICE NG123; NICE TA290; BNF and SMC dosing data; mirabegron SPC.
π© Refer urgently / specialist review
Visible haematuria (45+), or non-visible haematuria with dysuria/raised WCC (60+) β suspected cancer pathway.
Palpable bladder after voiding, suspected neurological disease, or a pelvic mass.
Persistent pain, recurrent UTI, previous continence or cancer surgery/pelvic radiotherapy, or symptomatic prolapse at or below the vaginal opening.
1οΈβ£1οΈβ£ Urological Cancers
Your job is recognition and the right pathway β treatment lives in secondary care
Kidney, bladder, prostate and testis
All thresholds are from NICE NG12 β unchanged in the April 2026 update.
Recognise
- β’Often found by chance on a scan done for something else
- β’Loin pain, mass and haematuria together is a late, uncommon picture
- β’Unexplained weight loss or appetite loss; raised calcium; high haemoglobin
- β’New left varicocele that doesn't empty lying down
Risk factors
- β’Smoking, obesity, hypertension
- β’Long-term dialysis; inherited syndromes (e.g. von HippelβLindau)
π© Suspected cancer pathway (NICE NG12)
45+ with unexplained visible haematuria without UTI, or visible haematuria persisting/recurring after UTI treatment.
Recognise
- β’Painless visible haematuria is the classic sign
- β’Storage symptoms without infection; recurrent UTIs in older people
Risk factors
- β’Smoking β the biggest single risk factor
- β’Work exposure to aromatic amines (dyes, rubber, paint)
- β’Older age, male sex, previous pelvic radiotherapy
π© Suspected cancer pathway (NICE NG12)
45+ with unexplained visible haematuria (no UTI), or visible haematuria persisting/recurring after UTI treatment.
60+ with unexplained non-visible haematuria and either dysuria or a raised white cell count.
Consider a non-urgent referral: 60+ with recurrent or persistent unexplained UTI.
When to offer PSA + DRE (NICE NG12)
- β’Any LUTS β nocturia, frequency, hesitancy, urgency, retention
- β’Erectile dysfunction
- β’Visible haematuria
- β’Bone or back pain, weight loss β think metastases
Risk factors
- β’Increasing age
- β’Black ethnicity
- β’Family history; BRCA2 variants
π© Suspected cancer pathway (NICE NG12)
PSA above the age-specific threshold: 40β49 over 2.5; 50β59 over 3.5; 60β69 over 4.5; 70β79 over 6.5 Β΅g/L.
Prostate feels malignant on DRE β refer whatever the PSA.
Recognise
- β’Painless, hard lump or change in shape/texture of the testis
- β’Most common in young to middle-aged men
- β’Dragging heaviness; occasionally breast enlargement
Act (NICE NG12)
- β’Consider a suspected cancer pathway referral for non-painful enlargement or change in shape/texture of the testis
- β’Consider direct-access ultrasound for unexplained or persistent testicular symptoms
| Cancer | Classic clue | NICE NG12 trigger |
|---|---|---|
| Kidney | Often incidental; haematuria, weight loss | 45+ unexplained visible haematuria (no UTI) |
| Bladder | Painless visible haematuria; smoker | 45+ visible haematuria; or 60+ non-visible + dysuria/raised WCC |
| Prostate | LUTS, ED, abnormal DRE, raised PSA | PSA above age threshold, or malignant-feeling DRE |
| Testis | Painless hard lump in a young man | Consider suspected cancer pathway Β± direct-access ultrasound |
Source: NICE NG12 (recommendations by site; update information April 2026).
1οΈβ£2οΈβ£ Red Flags & Emergencies
The few presentations where minutes or a same-day referral change the outcome
Must-not-miss urology and renal emergencies
If in doubt, pick up the phone.
π© Red Flags β Do Not Miss
Acute scrotal pain β torsion until proven otherwise: immediate surgical referral.
Fever + loin pain + stone β infected obstructed kidney: emergency urology.
Painful, palpable bladder and unable to pass urine β acute retention: catheterise.
Retention with back pain, saddle numbness or leg weakness β cauda equina: immediate emergency referral.
AKI with potassium 6.0+, fluid overload, anuria or sepsis β same-day admission.
Visible haematuria at 45+ β suspected cancer pathway, anticoagulated or not.
Recognise
- β’Sudden, severe one-sided scrotal pain, often with nausea/vomiting
- β’High-riding testis lying horizontally; absent cremasteric reflex
- β’Most common in adolescents, but possible at any age
Act
- β’Refer immediately for surgical exploration β don't delay for a scan
- β’The chance of saving the testis falls with every hour β ideally surgery within about 6 hours (NICE CKS scrotal pain)
Recognise
- β’Can't pass urine, with a painful, distended, palpable bladder
- β’Triggers: BPH, constipation, UTI/prostatitis, anticholinergics, opioids, after surgery or anaesthetic
Act
- β’Catheterise and record the residual volume drained
- β’Check U&E; treat the trigger (e.g. constipation, stop culprit drugs)
- β’Men with likely BPH: offer an alpha-blocker before a trial without catheter (NICE CG97)
- β’Same-day urology if AKI, infection, clots or failed catheterisation
- β’Assess for sepsis in anyone with UTI plus fever, confusion, low BP, high heart or breathing rate, or mottled skin (NICE NG51 sepsis risk stratification)
- β’Older people may just seem "off legs" or newly confused
- β’Known stone, catheter or prostate enlargement makes obstruction more likely
- β’45+ with unexplained visible haematuria β suspected cancer pathway (bladder + kidney)
- β’60+ with non-visible haematuria + dysuria or raised WCC β suspected cancer pathway (bladder)
Source: NICE NG12. See the Haematuria & Proteinuria section for the full pathway.
πͺ You've Got This!
A final word of encouragement before you head back to the coalface
You've Got This! πͺ
Remember: you don't need to be a nephrologist or a urologist to give excellent kidney and bladder care. You just need to know when to worry, when to treat, and when to refer.
You can confidently manage most UTIs, CKD monitoring, BP and statins, sick-day advice, and first-line treatment for prostate and bladder symptoms. Refer the ACR of 70, the falling eGFR, the raised PSA and the stone that won't pass. And the one thing never to miss: painless visible blood in the urine β however "obvious" the explanation seems.
β Now go reward yourself with that well-deserved coffeeBradford VTS is a FREE resource made with β€ by Dr. Ramesh Mehay and others.
Β© 2026 Renal & Urology Clinical Guide β educational resource for healthcare professionals. Always check current NICE guidance and the BNF before prescribing.